Spyre Therapeutics Inc. (SYRE) announced the pricing of its underwritten public offering of about 7.28 million shares of its common stock at a price to the public of $27.50 per share.
The company expects aggregate gross proceeds from the offering to be $200.0 million, before deducting underwriting discounts and commissions and other offering expenses.
In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1.09 million shares of the Company's common stock at the public offering price, less the underwriting discount.
The offering is expected to close on or about November 20, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.